Chemotherapy Dose Intensity Determination as a Quality of Care Measure for Managed Care Organizations in the Treatment of Early-Stage Breast Cancer

Abstract

The objective of this study was to demonstrate how a clinical practice database can be used to illustrate the variations in adjunctive chemotherapy for breast cancer, to describe a measure of dose intensity (DI) to monitor that variation, and to design interventions to maximize a full-planned dose. An arbitrary sample of oncology practices across the United States was selected, each providing data on 10-20 patients treated with adjuvant chemotherapy for early-stage breast cancer. Data on 17,566 patients from 1438 sites were collected, consisting of patient characteristics including age, number of positive nodes, planned and delivered chemotherapy agents, and a sample of absolute neutrophil or white blood cell counts by cycle. Mean age of the patient cohort was 48.5 years, and 54% of patients were below the age of 49. Treatment for the disease has changed during the 2 periods studied, 1983-1994 and 1995-1999. Use of Adriamycin/Cytoxan (AC) increased, whereas use of Cytoxan/Adriamycin/Fluorouracil (CAF) and full-dose Cytoxan/Methotrexate/Fluorouracil (CMF1) decreased. However, the less intense Cytoxan/Methotrexate/Fluorouracil combination (CMF2) has seen an actual increase in use during the 2 periods. Within the context of oncology care, including chemotherapy, full-dose intensive therapy and cure has always been the ultimate goal. In this study only 10% of the patients given AC received less than 85% of the full referenced dose, whereas about 20% of those receiving the other combinations fell into this category. Also, the summation dose intensity (SDI), a measure tying level of dose to survival, was highest in the AC group and lowest in the CMF2 group. Dose delays and dose reductions appear to account for the decrease in DI in the CMF1, CMF2, and CAF groups. DI, particularly SDI of adjuvant chemotherapy, which ties level of dose to survival in breast cancer patients, appears to be a reliable measure with which to assess the quality of care in community oncology practices. The 2 measures presented in this paper may be useful to managed care organizations for monitoring quality outcomes in this serious disease. Because one of the major reasons for reduction in chemotherapy dose appears to be neutropenia and its complications, these organizations can establish programs using DI as a basis for developing guidelines to optimize the clinical benefits of growth factors.

Keywords

Early-stage breast cancer practice patterns quality of care

Get full access to this article

View all access options for this article.

References

Greenlee RT , Murray T , Bolden S , et al. Cancer Statistics. CA Cancer J Clin. 2000;50:7-33.

Potosky A , Merrill R , Riley G , et al. Breast cancer survival and treatment in health maintenance organization and fee-for-service settings. J Natl Cancer Inst. 1997;89:1683-1691.

Taplin S , Barlow W , Urban N , et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 1995;87:417-426.

Tancini G , Bonadonna G , Valagussa P , et al. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol. 1983;1:2-10.

Weiss R , Valagussa P , Moliterni A , et al. Adjuvant chemotherapy after conservative surgery plus irradiation versus modified radical mastectomy: analysis of drug dosing and toxicity. Am J Med. 1987;83:455-463.

The Ludwig Breast Cancer Study Group . Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med. 1989;320: 491-496.

Fisher B , Brown A , Dimitrov N , et al. Two months of doxorubicine-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the national surgical adjuvant breast and bowel project B-15. J Clin Oncol. 1990;8:1483-1496.

Smalley R , Carpenter J , Bartolucci A , et al. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a southeastern cancer study group project. Cancer. 1977;40:625-632.

Bull J , Tormey D , Li S , et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 1978;41:1649-1657.

10.

Bonadonna G , Valagussa P , Moliterni A , et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332:901-906.

11.

Budman DR , Berry DA , Cirrincione CT , et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1998;90:1205-1211.

12.

Hryniuk W , Levine MN . Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986;4:1162-1170.

13.

Hryniuk W , Frei E III , Wright FA . A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol. 1998;16:3137-3147.

14.

Link BK , Budd GT , Scott S , et al [for the Oncology Practice Pattern Study Working Group ]. Delivering adjuvant chemotherapy to women with early stage breast carcinoma: current patterns of care. Cancer. 2001;92:1354-1367.